RADNOR, PA / ACCESSWIRE / December 21, 2017 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed in the United States District Court for the Southern District of New York against INC Research Holdings, Inc. (NASDAQ: INCR) (“INCR” or the “Company”) on behalf of purchasers of the Company’s securities between May 10, 2017 and November 9, 2017, inclusive (the “Class Period”).

Deadline Reminder: Investors who purchased INCR securities during the Class Period may, no later than January 30, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/inc-research-holdings-inc#join.

INCR provides clinical development services to pharmaceutical, biotechnology, and medical device companies.

On August 1, 2017, INCR announced that it completed a merger (the “Merger”) with inVentiv Health, Inc. (“inVentiv”). At that time, INCR represented to investors that the Merger was the beginning of an “industry-changing new company, purpose-built to achieve the singular goal of accelerating biopharmaceutical performance.”

The shareholder class action complaint alleges that Defendants made materially false and/or misleading statements, and failed to disclose material adverse facts, about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Merger was not providing the benefit that Defendants stated it would; (2) that inVentiv was underperforming; (3) that, as a result, the Company’s 2017 financial performance would be negatively impacted; and (4) that, as a result of the foregoing, Defendants’ statements about INCR’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On November 9, 2017, INCR reported a quarterly net loss from operations of $88.9 million (compared to income from operations of $39.4 million for the 2016 comparable quarter). The Company disclosed that its quarterly operating results – for the first quarter following the Merger – had been negatively impacted by: (i) Merger-related transaction expenses of $84.3 million, (ii) an impairment charge of $30.0 million, and (iii) an increase in amortization expense of $41.9 million due to the acquisition of intangible assets as a result of the Merger.

Following this news, shares of the Company’s stock declined $16.35 per share, or over 28%, to close on November 9, 2017 at $41.15 per share, on heavy trading volume. Over the following three trading days the Company’s shares declined an additional $6.80 per share.

INCR shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (888) 299 – 7706 or at info@ktmc.com.

INCR shareholders may, no later than January 30, 2018, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/inc-research-holdings-inc#join.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers, and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Darren J. Check, Esq.
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 484682

Industry Veteran with Proven Track Record in HIV Drug Development Bolsters Company’s Board with Scientific, Operational, and Financial Expertise

PORTLAND, OR / ACCESSWIRE / December 21, 2017 / Veana Therapeutics Inc., a biotechnology company focused on the development of novel oral therapies for the treatment of cancer to improve patients’ quality of life and bring hope to their families, today announced the appointment of Denis R. Burger, Ph.D. to its Board of Directors, effective immediately. Dr. Burger is a life sciences executive with over 28 years of extensive scientific, operational, and financial experience in the biotech industry.

As CEO or chairman of several biotechnology companies, Dr. Burger has led numerous corporate finance transactions and public securities offerings and has experience leading R&D, GMP manufacturing and clinical development functional areas. Additionally, he holds a patent for a method of detecting AIDS virus infection and oversaw the development of the first monoclonal antibody approved by the FDA for clinical use. Dr. Burger joins Veana’s board as the company prepares to advance the clinical development of VIMO-001, a proprietary oral immune modulator for the treatment of cancer.

“We are very pleased to welcome Dr. Burger to the Veana Therapeutics Board of Directors during this important time,” said Dr. Emmanuel Akporiaye, Veana’s Chairman of the Board. “Denis’ scientific and industry expertise, business acumen and experience in leading successful biotech companies will prove to be invaluable to the company.”

Dr. Burger commented, “The Veana management team and board of directors have identified a clear strategic path for its first-in-class, oral immune modulator, VIMO-001. I am excited to join Veana’s board of directors and truly believe VIMO-001 has the potential to change the treatment paradigm for cancer patients.”

Dr. Burger is currently Vice Chairman and Chief Science Officer of CytoDyn Inc, an HIV therapeutics, OTC-listed company. Dr. Burger is also currently lead independent director of Aptose Bioscience Inc., a cancer therapeutics, NASDAQ-listed company. Dr. Burger co-founded Trinity Biotech plc, a NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, and is currently lead independent director. Until March 2007, he was Chairman and Chief Executive Officer of AVI Biopharma Inc. (now Sarepta Therapeutics), a NASDAQ-listed RNA therapeutics company. He was also a co-founder of Epitope Inc. (now Orasure Technologies, NASDAQ-listed), serving as its Chairman from 1981 to 1990. Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health and Sciences University in Portland. Dr. Burger received his undergraduate degree in Bacteriology and Immunology from the University of California in Berkeley and his Master of Science and Ph.D. degrees in Microbiology and Immunology from the University of Arizona.

About VIMO-001

VIMO-001 belongs to a new class of multi-pathway oral anti-cancer therapeutics that selectively attack the mitochondria of rapidly dividing tumor cells to trigger cell death through both apoptosis and autophagy mechanisms. The resulting tumor cell death stimulates the release of “danger signals” such as heat shock proteins (HSPs), which contribute to the enhancement of the anti-cancer immune response via “auto-immunization.” VIMO-001 is stable at ambient temperatures and appears to be a powerful anti-cancer agent while not being a drug, leading to potentially fewer side effects and less frequent dosing requirements as compared to drug therapies currently in use.

About Veana Therapeutics

Veana Therapeutics is a Portland, Oregon-based clinical stage biotechnology company focused on developing novel oral immunotherapy products that safely and effectively treat cancer patients with minimal impact on quality of life. The Company’s lead product, VIMO-001, is being evaluated for safety in a first-in-human “all comers” Phase I clinical trial in patients with advanced cancers that have failed all prior therapies. The results to date are very encouraging as more than 75% of patients treated at the lowest two doses achieved stable disease and increased overall survival (OS) lasting from 1 month to 2 years. For more information on the company, please visit www.veana-therapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent Veana Therapeutics’ intentions, plans, expectations, and beliefs and are subject to risks, uncertainties and other factors, many beyond Veana Therapeutics’ control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words “believe,” “estimate,” “expect,” “intend,” “attempt,” “anticipate,” “foresee,” “plan,” and similar expressions and variations thereof identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made.

Veana Therapeutics disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information. While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of and expense associated with research, development, regulatory approval, and commercialization of Veana Therapeutics products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on Veana Therapeutics’ products and product candidates will be unfavorable; funding for additional clinical trials may not be available; Veana Therapeutics’ products may not receive marketing approval from regulators or, if approved, may fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of Veana Therapeutics’ products; Veana Therapeutics, its collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.

Veana Therapeutics is also subject to additional risks and uncertainties, including: risks associated with the actions of its corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property litigation; environmental and other risks; and risks that current and pending patent protection for its products may be invalid, unenforceable, or challenged or fail to provide adequate market exclusivity. There are also substantial risks arising out of Veana Therapeutics’ need to raise additional capital to develop its products and satisfy its financial obligations; the highly regulated nature of its business, including government cost-containment initiatives and restrictions on third-party payments for its products; and the highly competitive nature of its industry.

Mark Holifer
SVP
503-701-1618
mholifer@yahoo.com

SOURCE: Veana Therapeutics Inc.

ReleaseID: 484724

JAKARTA, INDONESIA / ACCESSWIRE / December 21, 2017 / KinerjaPay Corp. (KPAY), a secure digital payment and ecommerce platform in Indonesia, announced today details of its token sale plan. Blockchain Industries, Inc. (OTC PINK: OMGT), in partnership with Fintech Global Consultants, will be guiding KinerjaPay in their transition from an electronic payment platform to a token payment platform.

Operating in Southeast Asia’s largest economy, KinerjaPay is planning to raise up to US $5 million from its impending ICO (initial coin offerings). The ICO, or initial token offerings, will be offered to institutional or private investors in the form of KCOIN, KinerjaPay’s own proprietary virtual currency.

KCOIN (ticker symbol: KCOIN) is currently being traded among users on KinerjaPay’s platform for activities related to gamification, coin trading, online shopping, and multilevel marketing activities. With the ICO, KCOIN will be used as KinerjaPay’s cryptocurrency on one of the largest cryptocurrency exchanges in Asia.

“We believe this will be a game-changing move as we progress toward a much more advanced digital front,” said Edwin Witarsa Ng, CEO of KinerjaPay Corp. “The introduction of KCOIN allows us to expand our international reach in an efficient and effective manner while promoting our goal of a cashless society worldwide.”

Through their long-term partnership, Blockchain Industries and Fintech Global Consultants offer ICO consulting services worldwide. They have signed an agreement with KinerjaPay to build and launch their own cryptocurrency exchange to trade KCOIN and alt coins. Called KryptoPay, this unique trading platform will facilitate the transaction volume of KCOIN with other cryptocurrencies and serve as the international platform to trade KCOIN freely on the market. This move makes KinerjaPay the first Indonesian company to have an ownership in an international exchange.

“KinerjaPay is a leader in ecommerce and digital payments in Indonesia, and we’re excited to launch this initiative to help the greater public transact their banking with ease, efficiency and confidence,” said Patrick Moynihan, CEO of Blockchain Industries. “We believe KryptoPay will grow into a major public exchange for the Asian and worldwide markets.”

KinerjaPay will further extend its reach into ecommerce in the international market with the addition of multiple supplementary platforms, such as KryptoMall and KryptoGames, to its collection of crypto-based platforms.

About KinerjaPay

KinerjaPay is a secure digital payment and ecommerce platform. With convenient payment options through their secure web portal and mobile applications, KinerjaPay enables consumers to easily “Pay, Play and Buy” while shopping at their marketplace. Users can perform various payments quickly and safely, ranging from credit card payments to health insurance bills, and even direct fund transfers to individuals. KinerjaPay is planning to launch into other ecommerce verticals, such as delivery services, online gaming, and travel.

For more information on KinerjaPay, visit https://www.kinerjapay.com.

About Blockchain Industries, Inc.

Blockchain Industries is a diversified fintech holding company with a portfolio across multiple classes and verticals. The company invests in a broad range of alternative markets and cryptocurrency assets, with crypto banking, crypto trading and eco-mining, venture investing and ICO consulting, and media development and education as their four primary pillars of business. The company is headquartered in Puerto Rico, with corporate offices in Santa Monica and New York, and a satellite office in Tokyo.

For more information on Blockchain Industries, visit http://www.blockchainind.com.

About Fintech Global Consultants

Fintech Global Consultants is one of the world’s leading fintech consulting firms with over $1.1 billion under advisory from more than 6,400 clients in 82 countries. With a focus on wealth creation and preservation, the company has raised more than $150 million in initial coin offerings (ICO). Offering clients niche expertise and the highest level of service, their services include ICO launches, funding assistance, marketing and compliance, mining opportunities and crypto portfolio advisement.

For more information on Fintech Global Consultants, visit http://f-g-c.com.

SOURCE: Blockchain Industries, Inc.

ReleaseID: 484770

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free earnings report on JELD-WEN Holding, Inc. (NYSE: JELD). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JELD . The Company reported its third quarter fiscal 2017 operating results on November 07, 2017. The manufacturer of doors and windows exceeded revenue and earnings expectations and raised its outlook for the full fiscal year 2017. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, JELD-WEN Holding most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=JELD

Earnings Highlights and Summary

For the three months ended September 30, 2017, JELD-WEN’s net revenues jumped 6.3% to $991.4 million compared to $932.5 million for Q3 2016, driven by a growth in core revenues of 2%, a favorable impact of foreign exchange of 2%, and a contribution of 3% from recent acquisitions. The Company’s revenue numbers topped analysts’ expectations of $974.98 million.

For Q3 2017, JELD-WEN’s gross margin advanced 11.0% to $228.2 million compared to $205.7 million for Q3 2016, due to a profitable core growth, the contribution from recent acquisitions, and a non-recurring charge to material costs incurred in the same period of last year.

JELD-WEN’s selling, general, and administrative expenses (SG&A) advanced 9.9% to $142.6 million compared to $129.8 million for Q3 2016, due to higher legal costs and the impact of recent acquisitions. The Company’s SG&A as a percentage of net revenues was 14.4% versus 13.9% for the year-earlier comparable quarter.

JELD-WEN’s net income increased $5.2 million, or 11.3%, to $51.3 million in Q3 2017 compared to $46.1 million in Q3 2016. The Company’s earnings per share (EPS) was $0.47, and adjusted EPS was $0.55 for the reported quarter. The Company’s adjusted EPS was ahead of Wall Street’s estimates of $0.52 per share.

During Q3 2017, JELD-WEN’s adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) gained 8.7% to $128.2 million compared to $118.0 million in Q3 2016. The Company’s adjusted EBITDA margin expanded 20 basis points to 12.9% in the reported quarter from 12.7% in the year-earlier corresponding quarter.

Segment Results

During Q3 2017, JELD-WEN’s net revenues in the North America segment grew 3.6% to $572.0 million on a y-o-y basis, due to an increase in core revenues of 2%, and a contribution from recent acquisitions of 2%. The core revenue growth was primarily due to favorable pricing. The region’s adjusted EBITDA increased 4.8% to $82.5 million on a y-o-y basis, while adjusted EBITDA margin expanded 10 basis points to 14.4%.

For Q3 2017, JELD-WEN’s revenue from the Europe segment advanced 7.4% to $265.1 million on a y-o-y basis, primarily due to a 4% favorable impact from foreign exchange, a 2% from the contribution of recent acquisitions, and a 1% contribution from core growth. The segment’s adjusted EBITDA grew 6.2% to $33.4 million on a y-o-y basis, while adjusted EBITDA margin decreased 10 basis points to 12.6%. The decrease in adjusted EBITDA margin was primarily due to a timing difference in the UK of pricing initiatives lagging material cost inflation.

During Q3 2017, JELD-WEN’s Australasia segment’s net revenues surged 15.7% to $154.3 million, primarily due to the contribution from recent acquisitions of 8%, a core growth of 4%, and a 4% favorable impact of foreign exchange. The segment’s adjusted EBITDA jumped 28.4% to $22.9 million, and adjusted EBITDA margin expanded 140 basis points to 14.8%.

Balance Sheet and Cash Flow

JELD-WEN’s cash and cash equivalents as of September 30, 2017, were $219.5 million compared to $102.7 million as of December 31, 2016. The Company’s total debt as of September 30, 2017, was $1.25 billion compared to $1.62 billion as of December 31, 2016.

On February 01, 2017, JELD-WEN received net proceeds from its IPO of $472.4 million, and used a portion of these proceeds to repay $375.0 million of debt. In conjunction with the debt repayment in Q1 2017, the Company wrote off $7.0 million of original issue discount and deferred financing fees.

JELD-WEN’s cash flow from operations improved $63.9 million to $174.1 million in the first nine months of 2017 from $110.2 million in the year-ago same period. The Company’s free cash flow improved $94.0 million to $141.7 million in the first nine months of 2017 from $47.7 million in the comparable period of last year.

Annual Outlook

For the full year 2017, JELD-WEN is forecasting revenue growth of 2.0% to 4.0% on a y-o-y basis compared to the previous range of 1.5% to 3.5%. The Company is estimating adjusted EBITDA in the band of $440 million to $450 million compared to the previous range of $440 million to $460 million. JELD-WEN is forecasting capital expenditure to be in the band of $60 million to $70 million, reduced from the previous range of $80 million to $90 million.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, JELD-WEN Holding’s stock ended the trading session flat at $38.94.

Volume traded for the day: 278.66 thousand shares.

Stock performance in the last month – up 1.33%; previous three-month period – up 15.17%; past six-month period – up 12.54%; and year-to-date – up 49.08%

After yesterday’s close, JELD-WEN Holding’s market cap was at $4.10 billion.

The stock is part of the Industrial Goods sector, categorized under the General Building Materials industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484759

An EPLI Policy is Designed to Protect Business Owners from Potential Liability in the Event of a Sexual Harassment Lawsuit

NEW YORK, NY / ACCESSWIRE / December 21, 2017 / The founders of EK Insurance, a company that specializes in providing general liability insurance quotes, are also able to help business owners get quotes for Employment Practices Liability Insurance.

To learn more about Employment Practices Liability Insurance, which is also known as EPLI, please check out https://ekinsurance.com/employment-practices-liability-insurance.html.

As a company spokesperson noted, although numerous stories involving sexual harassment in the workplace appear on the news every day, many business owners are unaware that there is insurance available that can help pay the costs to defend them from unfair claims. The EPLI insurance policy protects from a potential sexual harassment claim, as well as claims regarding on the job discrimination, or if an employee says they were improperly dismissed or disciplined for any reason.

“Due to the sheer fact that as a business owner, you are always under a potential threat where a disgruntled employee might attempt to sue you, or claim you were irresponsible in dealing with them – for example, due to issues with termination or discipline such as suspending them – it is worth your while to consider purchasing an EPLI insurance policy to protect your business,” the spokesperson noted, adding that for business owners in the state of New York, they are typically able to purchase this type of insurance for as little as $37 a month.

To watch a short YouTube video that illustrates how and when an EPLI policy may be needed, as well as explains more about this type of liability insurance, please visit https://youtu.be/5FZMDFR7Pnc.

To help fully understand what EPLI insurance is all about, business owners are welcome to visit EK Insurance to read up on this type of policy and understand the various EPLI policy terms.

Business owners who are interested in getting a quote for an EPLI policy are also welcome to visit the user-friendly EK Insurance website at any time. There, they can fill out and submit a short form that will quickly provide them with free quotes.

About EK Insurance:

At EK Insurance, they come to work every day because they want to protect their clients from the risks they face in life and business. The goal at EK Insurance is to make the insurance purchasing experience as quick and painless as possible. They provide professional and direct insurance advice to their clients. EK Insurance is a licensed professional insurance agency in California, Delaware, Kentucky, New Jersey, New York, Pennsylvania and Texas. They care about their clients and know that their success is their success. For more information, please visit https://ekinsurance.com/.

EK Insurance
99 Wall St. #1234
New York, NY 10005

Contact:

Ethan Kosmin
info@ekinsurance.com
484 800-1000

SOURCE: EK Insurance

ReleaseID: 484768

During His Recent Trip to Uganda, Mark Worked with Two Organisations: PILAC and APP

LONDON, UK / ACCESSWIRE / December 21, 2017 / Criminal barrister Mark Kelly recently traveled to Uganda to work with local lawyers fighting for justice. In his own words below, Mark describes his vital work and life-changing experience there.

To find out more about Mark’s criminal services here in the UK, please visit: https://www.markkellybarrister.co.uk/practice-areas.html.

Whilst in Uganda, Mark worked with PILAC (Public Interest Law Centre), and APP (the African Prisoners Project). As he noted, PILAC is a fantastic organization, whose vision is to build a legal profession alive to the social justice needs of the poor and vulnerable through legal education, research, legal aid, public interest litigation and by building strategic partnerships.

PILAC is associated with Makerere University and it provides legal aid to members of the local surrounding community according to need. As an organization, it is donor-funded by the Democratic Governance Facility. PILAC disseminates information to the local communities who may not be aware of their legal rights. It also trains students who go into the communities as part of an outreach programme and increases knowledge of those they interact with on legal issues which can cover marriage; land issues; inheritance and wills; criminal procedure; drug abuse; domestic violence and children’s rights. It comprises of a team of dedicated and committed lawyers.

Mark met with Veronica Kange and was astounded by the work done by PILAC. Nobody is turned away by PILAC, which is impressive in its own right when one considers the numbers of people in the local communities needing legal services. Clients attend without an appointment and the organization liaises with local leaders in the community to identify the contemporaneous issues and the leaders act as a referral agency for members of the community.

“PILAC have forged links with the African Prisoners Project, who work together to provide legal aid to inmates, as well as regularly providing guest lectures, tours for students, and organizing moot competitions,” Mark noted, adding that the main hurdles to PILAC growing and extending its influence are logistics and resources.

“PILAC is building bridges with the African Prisoners Project. I am sure the officers of PILAC will have a meeting of minds with the officers of APP because it too is a highly impressive organization.”

To read more about Mark’s fascinating trip to Uganda, please visit: https://www.markkellybarrister.co.uk/Insights.html.

About Mark Kelly:

Mark Kelly is a defense barrister, having been called to the bar in 1985, giving him more than 30 years of experience in expert criminal and regulatory defense. He has extensive experience in both domestic and international work. Mark has worked as a stagiaire in DGIV (Competition) in the European Commission in Brussels, giving him excellent insight into both regulatory offenses and fraud. Furthermore, he studied European Law at the College of Europe (Bruges) and he is currently a member of the Bar European Group and the European Lawyers Bar Association. For more information, please visit https://www.markkellybarrister.co.uk/.

Contact:

Mark Kelly
MRK@no5.com
+44 020 8108 7186

SOURCE: Mark Kelly

ReleaseID: 484767

Proactive Effort to Focus on Increasing Awareness and Enhancing Shareholder Value

MIGDAL HA’EMEK, ISRAEL / ACCESSWIRE / December 21 , 2017 / PV Nano Cell, Ltd. (OTCQB: PVNNF) (“PV Nano Cell” or the “Company”), an innovative producer of conductive digital inks, announced today that it has retained Hayden IR, a national investor relations consulting firm, to implement a strategic investor relations program grounded in best practices. Hayden IR will work to raise PV Nano Cell’s visibility within the investment community by strengthening its relationships and increasing awareness with the goal of ultimately enhancing shareholder value.

“Now that we have closed on the acquisition of DigiFlex and are expecting to ramp up of commercialization efforts in 2018, the board and management believed it was an appropriate time to retain a more proactive strategic investor relations firm to help us reach new potential investors and effectively communicate our investment thesis,” said Fernando de la Vega, PV Nano Cell’s Chief Executive Officer. “We believe our conductive digital inks coupled with our “complete solution” approach provides a differentiated value-add in digital printing in mass production of electronics and we are well positioned to take advantage of an increasing amount of opportunities in our targeted markets. We are confident that throughout their national footprint, Hayden IR will help us more effectively communicate our accelerated growth strategy, business objectives and corporate milestones to a wider audience of sophisticated investors.”

Hayden IR is a highly regarded investor relations consulting firm known for its ability to connect underfollowed and undervalued emerging growth companies with sophisticated institutional investors, buy-side and sell-side analysts, retail brokerage firms and accredited individual investors. Leveraging decades of cumulative experience, Hayden IR develops strategies to help clients effectively communicate with the investment community and works to increase their exposure through targeted outreach and transparent positioning. Hayden IR helps public companies deliver the right message to the right audience. Over time, Hayden IR helps its clients navigate up the Wall Street value chain and to help them secure a reasonable valuation by broadening their audience, expanding institutional ownership and ensuring clear, consistent communication with the public.

PV Nano Cell, Ltd.

PV Nano Cell has developed innovative conductive inks for use in printed electronics (PE) and solar photovoltaics (PV) applications. PV Nano Cell’s Sicrys™ ink family is a single-crystal, nanometric silver conductive ink delivering enhanced performance. Sicrys™ is also available in copper-based form, delivering all of the product’s properties and advantages with improved cost efficiency. Sicrys™ conductive inks are used all over the world in a range of inkjet printing applications, including photovoltaics, printed circuit boards, antennas, sensors, touchscreens and other applications. For more information, please visit www.PVNanoCell.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” All information set forth in this news release, except historical and factual information, represents forward-looking statements. This includes all statements about the Company’s plans, beliefs, estimates, and expectations. These statements are based on current estimates and projections, which involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include issues related to: rapidly changing technology and evolving standards in the industries in which the Company operates; the ability to obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new business, and sign new agreements. For a more detailed description of the risks and uncertainties affecting PV Nano Cell, reference is made to the Company’s latest Annual Report on Form 20-F which is on file with the Securities and Exchange Commission (SEC) and the other risk factors discussed from time to time by the Company in reports filed with, or furnished to, the SEC. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Investors Contact:

Hayden IR
hart@haydenir.com
(917) 658-7878

SOURCE: PV Nano Cell, Ltd.

ReleaseID: 484719

Industry Leader Recognized for Reducing Compliance Costs via Collaborative Compliance

DREXEL HILL, PA / ACCESSWIRE / December 21, 2017 / Trust Exchange, the leader in Collaborative Business Information Services, today announced that RegTech Markets, a global community of thought leaders, innovators, and investors, has named Trust Exchange to its RegTech 50 list of the top providers in regulatory and compliance technologies.

RegTech Markets evaluated more than 600 products and services from notable regulatory technology providers, like BearingPoint, Nasdaq, KPMG, and others. The Top 50 was based on voting from regulated companies globally to identify the top solutions for improving compliance processes. The growing interest in regulatory and compliance solutions is driven by increasing regulation and growing frustration with traditional business information services and manual compliance processes.

Compliance costs are soaring based on the growing volume and complexity of business relationships. A study from Juniper Research recently showed that companies spent more than $10B USD globally on compliance in 2017, and predicted that compliance costs will skyrocket to more than $76B USD by 2022[1].

”Yesterday’s approach to compliance won’t solve the problems of tomorrow,” said Ed Sullivan, Founder and CEO of Trust Exchange. ”You can’t just throw people and manual processes at a problem of this scale. That’s why more institutions are turning to new technologies and methods like crowdsourcing, Artificial Intelligence (AI), gamification, and blockchain to digitize costly and cumbersome compliance processes.”

Along with providing a crowdsourced platform for overall vendor management, Trust Exchange enables Collaborative Compliance. The Trust Exchange Community is a community of businesses who securely disclose and monitor key information to increase their trust in each other. The company was founded by a father and son team of entrepreneurs who were both frustrated with the current state of business information applications. The data available was stale and delivered via printable reports or email. It wasn’t timely, predictive and certainly not actionable. Furthermore, the business information and B2B credit bureaus kept this stale information behind a two-way paywall and charged companies to correct and update their information.

Exchanging and monitoring this information is a complex problem that has grown exponentially with the growth of outsourcing and regulation. Trust Exchange solves compliance challenges by providing a platform where businesses can directly and securely exchange key information required to do business with each other. This can be as simple as disclosing the number of employees and insurance to complex certifications or audits.

Trust Exchange has also launched an industry benchmark to assess the state of today’s compliance and vendor management processes to understand the current challenge institutions are facing, and identify common themes across top-performing companies. Survey participants will receive a complimentary copy of the summarized survey findings to evaluate their own processes compared to their peers.

To learn more about the survey and to participate, please visit http://www.trustexchange.com/blog/2017/12/18/vendor-management-survey.

To learn more about Trust Exchange and to join for free, visit https://web.trustexchange.com/register.php.

About Trust Exchange

Trust Exchange is disrupting the $40B Business Information Services market by enabling companies to securely disclose and monitor key information about customers, vendors, and partners with a centralized, secure cloud platform. Trust Exchange provides Collaborative Compliance, dramatically lowering the cost of compliance by helping institutions automate critical compliance activities, build deeper trust with customers, vendors, and partners, and monitor their own company’s reputation performance over time. The company was founded in 2011 by CEO Ed Sullivan, a serial entrepreneur who has created multiple successful startups, and his son Edward Sullivan III who is the company’s lead architect. Today, Trust Exchange has tens of thousands of individual members as well as hundreds of customer institutions. Leaders like Nasa, Sodexo, Xerox and others count on Trust Exchange to streamline vendor management and compliance processes and deepen their trusted business relationships.

For more information, visit www.trustexchange.com.

Follow @b2btrust on Twitter
Follow Trust Exchange in LinkedIn at https://www.linkedin.com/company/15218284/
Read the Trust Exchange blog at http://www.trustexchange.com/blog/
Become a fan of Trust Exchange on Facebook: https://www.facebook.com/TrustExchange/

CONTACT:

Ed Sullivan
Trust Exchange
edsull@trustexchange.com

[1] Juniper Research, ”Regtech Strategies for Financial Services 2017-2022,” October 22, 2017

SOURCE: Trust Exchange

ReleaseID: 484732

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors free stock reports for this morning include these Toronto Exchanges’ equities from the Restaurants industry: Restaurant Brands International, Boston Pizza Royalties Income Fund, MTY Food Group, and Imvescor Restaurant Group. Access our complimentary up-to-the-minute research reports by becoming an online member now:

www.active-investors.com/registration-sg

The S&P/TSX Composite Index progressed 26.32 points, or 0.16%, to close Wednesday’s trading session at 16,159.67. The TSX Venture Exchange gained 0.73 points, or 0.09%, to finish at 805.69.

Today’s stocks of interest consist of Restaurant Brands International Inc. (TSX: QSR), Boston Pizza Royalties Income Fund (TSX: BPF-UN), MTY Food Group Inc. (TSX: MTY), and Imvescor Restaurant Group Inc. (TSX: IRG). Click the link below to view a sample of the free research report that will be available to you as a member of Active-Investors:

www.active-investors.com/registration-sg

Restaurant Brands International Inc.

Oakville, Canada headquartered Restaurant Brands International Inc.’s stock edged 0.28% higher, to finish Wednesday’s session at $78.60 with a total volume of 656,626 shares traded. Restaurant Brands’ shares have gained 22.26% in the past year. The Company’s shares are trading below its 50-day and 200-day moving averages. Restaurant Brands International’s 50-day moving average of $81.45 is above its 200-day moving average of $79.65. Shares of the Company, which owns, operates, and franchises quick-service restaurants under the Tim Hortons and Burger King brand names, are trading at a PE ratio of 54.51. View the research report on QSR.TO at:

www.active-investors.com/registration-sg/?symbol=QSR

Boston Pizza Royalties Income Fund

On Wednesday, shares in Boston Pizza Royalties Income Fund recorded a trading volume of 3,398 shares. The stock ended the day 0.16% lower at $22.25. Boston Pizza Royalties Income Fund’s stock has advanced 1.64% in the past three months. The Company’s shares are trading above its 50-day and 200-day moving averages. The stock’s 200-day moving average of $22.19 is above its 50-day moving average of $22.11. Shares of Boston Pizza Royalties Income, which operates as a limited purpose open-ended trust, are trading at a PE ratio of 19.87.

Get the free report on BPF-UN.TO at:

www.active-investors.com/registration-sg/?symbol=BPF.UN

MTY Food Group Inc.

On Wednesday, shares in Saint-Laurent, Canada headquartered MTY Food Group Inc. ended the session 0.16% lower at $54.81 with a total volume of 44,402 shares traded. MTY Food’s shares have advanced 0.07% in the last month and 15.88% in the previous three months. Furthermore, the stock has gained 8.07% in the past one year. The stock is trading above its 50-day and 200-day moving averages. Furthermore, the stock’s 50-day moving average of $52.48 is greater than its 200-day moving average of $48.55. Shares of the Company, which franchises and operates quick-service restaurants and casual dining concepts in Canada, the US, and internationally, are trading at a PE ratio of 19.12. Access the most recent report coverage on MTY.TO at:

www.active-investors.com/registration-sg/?symbol=MTY

Imvescor Restaurant Group Inc.

Montreal, Canada headquartered Imvescor Restaurant Group Inc.’s stock closed the day 0.71% higher at $4.23. The stock recorded a trading volume of 873,359 shares, which was above its three months average volume of 276,642 shares. Imvescor Restaurant’s shares have gained 1.20% in the last month, 11.90% in the past three months, and 27.41% in the previous year. The Company’s shares are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $4.09 is greater than its 200-day moving average of $3.74. Shares of the Company, which operates franchised and corporate restaurants under the Pizza Delight, Toujours Mikes, Scores, and Bâton Rouge brands in Eastern Canada, are trading at a PE ratio of 20.43. Today’s complimentary report on IRG.TO can be accessed at:

www.active-investors.com/registration-sg/?symbol=IRG

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484738